Status:
WITHDRAWN
Assessing the Impact of Varenicline on Brain-Behavior Vulnerability
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Varenicline and the Blunting of Cocaine Cues
Eligibility:
MALE
18-55 years
Phase:
PHASE2
Brief Summary
Our proposal will enable us to study cocaine patients to determine whether varenicline can weaken brain arousal to drug cues in an fMRI imaging setting, which is what we theorize. This supplement supp...
Eligibility Criteria
Inclusion
- Physically healthy male substance abuse subjects age 18-55.
Exclusion
- 1\) Participation in clinical trial and receipt of investigational drug(s) during previous 60 days 2) Clinically significant cardiovascular, hematologic, hepatic, renal, neurological or endocrinological abnormalities 3) History of serious head trauma or injury causing loss of consciousness that lasted more than 3 minutes. 4) Presence of magnetically active prosthetics, plates, pins, broken needles, permanent retainer, bullets, etc. in subject's body (unless a radiologist confirms that its presence is unproblematic). A x-ray may be obtained to determine eligibility. 5) Claustrophobia or other medical condition disabling subject from lying in the MRI for approximately 60 minute
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00895557
Start Date
December 1 2007
End Date
December 1 2013
Last Update
September 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania Treatment Research Center
Philadelphia, Pennsylvania, United States, 19104